CD1d-restricted natural killer T cells: Roles in tumor immunosurveillance and tolerance

Transfusion Medicine and Hemotherapy

Volumn 33, Issue 1, 2006, Pages 18-36

  Jerud, Elliot S ^a   Bricard, Gabriel ^a   Porcelli, Steven A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

CD1d; Immune tolerance; Lipid antigens; Neoplasm; NKT cells

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA GALACTOSYLCERAMIDE; BETA 2 MICROGLOBULIN; CD161 ANTIGEN; CD1D ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGRAFT; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DERMATOMYOSITIS; EPSTEIN BARR VIRUS; FIBROSARCOMA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; KIDNEY ALLOGRAFT; KNOCKOUT MOUSE; LEUKEMIA; LUNG CARCINOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE STRAIN; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SARCOMA; SJOEGREN SYNDROME; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; THYMUS; TUMOR CELL LINE; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT;

EID: 33644530404     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090193     Document Type: Review

References (195)

1. Godfrey DI, Kronenberg M: Going both ways. Immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004;114:1379-1388.
2. Dascher CC, Brenner MB: CD1 antigen presentation and infectious disease. Contrib Microbiol 2003;10:164-182.
3. Skold M, Behar SM: The role of group 1 and group 2 CD1-restricted T cells in microbial immunity. Microbes Infect 2005;7:544-551.
4. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L: NKT Cells. What's in a Name? Nat Rev 2004;4:231-237.
5. Van der Vliet HJ, Nishi N, Koezuka Y, Peyrat MA, von Blomberg BM, van den Eertwegh AJ, Pinedo HM, Giaccone G, Scheper RJ: Effects of alpha- galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human Valpha24+ Vbeta11+ T cells. Immunology 1999;98:557-563.
6. Vivier E, Anfossi N: Inhibitory NK-cell receptors on T cells. Witness of the past, actors of the future. Nat Rev Immunol 2004;4:190-198.
7. Pellicci DG, Hammond KJ, Uldrich AP, Baxter AG, Smyth MJ, Godfrey DI: A natural killer T (NKT) cell developmental pathway involving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med 2002;195: 835-844.
8. Benlagha K, Kyin T, Beavis A, Teyton L, Bendelac A: A thymic precursor to the NK T cell lineage. Science 2002;296:553-555.
9. Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang CR, Joyce S, Wick MJ, Van Kaer L: The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 2003;100:10913-10918.
10. Kambayashi T, Assarsson E, Michaelsson J, Berglund P, Diehl AD, Chambers BJ, Ljunggren HG: Emergence of CD8+ T cells expressing NK cell receptors in influenza A virus-infected mice. J Immunol 2000;165:4964-4969.
11. Yrlid U, Petersson E, Dohlsten M, Hedlund G: TCR alpha beta+ anti-tumor cytolytic T lymphocytes express NKR-P1 while the anti-tumor activity of TCR gamma delta+ T lymphocytes is not correlated to NKR-P1 expression. Cell Immunol 1996;173:287-294.
12. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR: CD1 recognition by mouse NK1+ T lymphocytes. Science 1995;268:863-865.
13. Lantz O, Bendelac A: An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 1994;180:1097-1106.
14. Porcelli S, Yockey CE, Brenner MB, Balk SP: Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8-alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med 1993;178:1-16.
15. Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A: An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8-T cells. J Exp Med 1994;180:1171-1176.
16. Koseki H, Imai K, Ichikawa T, Hayata I, Taniguchi M: Predominant use of a particular alpha-chain in suppressor T cell hybridomas specific for keyhole limpet hemocyanin. Int Immunol 1989;1:557-564.
17. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M: CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-1629.
18. Natori T, Morita M, Akimoto K, Koezua Y: Agesphalins, novel antitumor and immunostimulatory cerebrosides from the marine sponge Agelas Mauritianus. Tetrahedron 1994;50:2771-2784.
19. Morita M, Motoki K, Akimoto K, Natori T, Sakai T, Sawa E, Yamaji K, Koezuka Y, Kobayashi E, Fukushima H: Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 1995;38:2176-2187.
20. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A: In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med 2000;191:1895-1903.
21. Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, Koezuka Y, Kronenberg M: Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000;192:741-754.
22. Apostolou I, Cumano A, Gachelin G, Kourilsky P: Evidence for two subgroups of CD4-CD8- NKT cells with distinct TCR alpha beta repertoires and differential distribution in lymphoid tissues. J Immunol 2000;165:2481-2490.
23. Behar SM, Cardell S: Diverse CD1d-restricted T cells: diverse phenotypes, and diverse functions. Semin Immunol 2000;12:551-560.
24. Lanier LL, Chang C, Phillips JH: Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994;153:2417-2428.
25. Hammond KJ, Pellicci DG, Poulton LD, Naidenko OV, Scalzo AA, Baxter AG, Godfrey DI: CD1d-restricted NKT cells. An interstrain comparison. J Immunol 2001;167:1164-1173.
26. Exley MA, Koziel MJ: To be or not to be NKT. Natural killer T cells in the liver. Hepatology 2004;40:1033-1040.
27. Prell C, Konstantopoulos N, Heinzelmann B, Frankenberger B, Reinhardt D, Schendel DJ, Krauss-Etschmann S: Frequency of Valpha24+ CD161+ natural killer T cells and invariant TCRAV24-AJ18 transcripts in atopic and non-atopic individuals. Immunobiology 2003;208:367-380.
28. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A: Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002;110:793-800.
29. Kim CH, Johnston B, Butcher EC: Trafficking machinery of NKT cells. Shared and differential chemokine receptor expression among Va24+ Vb11+ NKT cell subsets with distinct cytokine-producing capacity. Blood 2002;100:11-16.
30. Moody DB, Zajonc DM, Wilson IA: Anatomy of CD1-lipid antigen complexes. Nat Rev Immunol 2005;5:387-399.
31. Porcelli SA: The CD1 family. A third lineage of antigen-presenting molecules. Adv Immunol 1995;59:1-98.
32. De Libero G, Mori L: Recognition of lipid antigens by T cells. Nat Rev Immunol 2005;5:485-496.
33. Han M, Hannick LI, DiBrino M, Robinson MA: Polymorphism of human CD1 genes. Tissue Antigens 1999;54:122-127.
34. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, Kronenberg M: CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998;188:1521-1528.
35. Brossay L, Jullien D, Cardell S, Sydora BC, Burdin N, Modlin RL, Kronenberg M: Mouse CD1 is mainly expressed on hemopoietic-derived cells. J Immunol 1997;159:1216-1224.
36. Spada FM, Borriello F, Sugita M, Watts GF, Koezuka Y, Porcelli SA: Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells. Eur J Immunol 2000;30:3468-3477.
37. Exley M, Garcia J, Wilson SB, Spada F, Gerdes D, Tahir SM, Patton KT, Blumberg RS, Porcelli S, Chott A, Balk SP: CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology 2000;100:37-47.
38. Roark JH, Park SH, Jayawardena J, Kavita U, Shannon M, Bendelac A: CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells. J Immunol 1998;160:3121-3127.
39. Campbell N, Yio XY, So LP, Li Y, Mayer L: The intestinal epithelial cell. Processing and presentation of antigen to the mucosal immune system. Immunol Rev 1999;172:315-324.
40. Bonish B, Jullien D, Dutronc Y, Huang BB, Modlin R, Spada FM, Porcelli SA, Nickoloff BJ: Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 2000;165:4076-4085.
41. Tsuneyama K, Yasoshima M, Harada K, Hiramatsu K, Gershwin ME, Nakanuma Y: Increased CD1d expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis. Hepatology 1998;28:620-623.
42. Dao T, Guo D, Ploss A, Stolzer A, Saylor C, Boursalian TE, Im JS, Sant'Angelo DB: Development of CD1d-restricted NKT cells in the mouse thymus. Eur J Immunol 2004;34:3542-3552.
43. Sandberg JK, Stoddart CA, Brilot F, Jordan KA, Nixon DF: Development of innate CD4+ alpha-chain variable gene segment 24 (Valpha24) natural killer T cells in the early human fetal thymus is regulated by IL-7. Proc Natl Acad Sci USA 2004;101:7058-7063.
44. Moody DB, Porcelli SA: Intracellular pathways of CD1 antigen presentation. Nat Rev Immunol 2003;3:11-22.
45. Koch M, Stronge VS, Shepherd D, Gadola SD, Mathew B, Ritter G, Fersht AR, Besra GS, Schmidt RR, Jones EY, Cerundolo V: The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol 2005;6:819-826.
46. Zajonc DM, Cantu C 3rd, Mattner J, Zhou D, Savage PB, Bendelac A, Wilson IA, Teyton L: Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol 2005;6:810-818.
47. Yu KO, Im JS, Molano A, Dutronc Y, Illarionov PA, Forestier C, Fujiwara N, Arias I, Miyake S, Yamamura T, Chang YT, Besra GS, Porcelli SA: Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci USA 2005;102:3383-3388.
48. Goff RD, Gao Y, Mattner J, Zhou D, Yin N, Cantu C 3rd, Teyton L, Bendelac A, Savage PB: Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 2004;126:13602-13603.
49. Miyamoto K, Miyake S, Yamamura T: A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001;413:531-534.
50. Brossay L, Naidenko O, Burdin N, Matsuda J, Sakai T, Kronenberg M: Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells. J Immunol 1998;161: 5124-5128.
51. Wu D, Xing GW, Poles MA, Horowitz A, Kinjo Y, Sullivan B, Bodmer-Narkevitch V, Plettenburg O, Kronenberg M, Tsuji M, Ho DD, Wong CH: Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci USA 2005;102:1351-1356.
52. Schmieg J, Yang G, Franck RW, Tsuji M: Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-galactosylceramide. J Exp Med 2003;198:1631-1641.
53. Schmieg J, Yang G, Franck RW, van Rooijen N, Tsuji M: Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc Natl Acad Sci USA 2005;102:1127-1132.
54. Stanic AK, Shashidharamurthy R, Bezbradica JS, Matsuki N, Yoshimura Y, Miyake S, Choi EY, Schell TD, van Kaer L, Tevethia SS, Roopenian DC, Yamamura T, Joyce S: Another view of T cell antigen recognition. Cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor. J Immunol 2003;171:4539-4551.
55. Oki S, Chiba A, Yamamura T, Miyake S: The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 2004;113:1631-1640.
56. Ait Slimane T, Hoekstra D: Sphingolipid trafficking and protein sorting in epithelial cells. FEBS Letters 2002;529:54-59.
57. Park YK, Lee JW, Ko YG, Hong S, Park SH: Lipid rafts are required for efficient signal transduction by CD1d. Biochem Biophys Res Commun 2005;327:1143-1154.
58. Lang GA, Maltsev SD, Besra GS, Lang ML: Presentation of alpha-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts. Immunology 2004;112:386-396.
59. Castano AR, Tangri S, Miller JE, Holcombe HR, Jackson MR, Huse WD, Kronenberg M, Peterson PA: Peptide binding and presentation by mouse CD1. Science 1995;269:223-226.
60. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, Ho DD, Tsuji M, Kawahara K, Wong CH, Kronenberg M: Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005;434:520-525.
61. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C 3rd, Zhou D, Saint-Mezard P, Wang V, Gao Y, Yin N, Hoebe K, Schneewind O, Walker D, Beutler B, Teyton L, Savage PB, Bendelac A: Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005;434:525-529.
62. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR: Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 2005;35:1692-1701.
63. Fischer K, Scotet E, Niemeyer M, Koebernick H, Zerrahn J, Maillet S, Hurwitz R, Kursar M, Bonneville M, Kaufmann SH, Schaible UE: Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci USA 2004;101:10685-10690.
64. Amprey JL, Im JS, Turco SJ, Murray HW, Illarionov PA, Besra GS, Porcelli SA, Spath GF: A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med 2004;200:895-904.
65. De Silva AD, Park JJ, Matsuki N, Stanic AK, Brutkiewicz RR, Medof ME, Joyce S: Lipid protein interactions. The assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum. J Immunol 2002;168:723-733.
66. Park JJ, Kang SJ, De Silva AD, Stanic AK, Casorati G, Hachey DL, Cresswell P, Joyce S: Lipid-protein interactions. Biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conserved. Proc Natl Acad Sci USA 2004;101:1022-1026.
67. Zhou D, Mattner J, Cantu C 3rd, Schrantz N, Yin N, Gao Y, Sagiv Y, Hudspeth K, Wu YP, Yamashita T, Teneberg S, Wang D, Proia RL, Levery SB, Savage PB, Teyton L, Bendelac A: Lysosomal glycosphingolipid recognition by NKT cells. Science 2004;306:1786-1789.
68. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI: NKT cells. Conductors of tumor immunity? Curr Opin Immunol 2002;14:165-71.
69. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC: Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003;17:1068-1077.
70. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, Kondo E, Harada M, Koseki H, Nakayama T, Tanaka Y, Taniguchi M: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 1998;95:5690-5693.
71. Nakagawa R, Motoki K, Ueno H, Iijima R, Nakamura H, Kobayashi E, Shimosaka A, Koezuka Y: Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res 1998;58:1202-1207.
72. Chamoto K, Takeshima T, Kosaka A, Tsuji T, Matsuzaki J, Togashi Y, Ikeda H, Nishimura T: NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo. Immunol Lett 2004;95:5-11.
73. Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, van Kaer L, Saiki I, Okumura K: Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 2001;31:1720-1727.
74. Crowe NY, Uldrich AP, Kyparissoudis K, Hammond KJ, Hayakawa Y, Sidobre S, Keating R, Kronenberg M, Smyth MJ, Godfrey DI: Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J Immunol 2003;171:4020-4027.
75. Parekh W, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, Joyce S, Van Kaer L: Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005;115: 2572-2583.
76. Bendelac A, Bonneville M, Kearney JF: Autoreactivity by design. Innate B and T lymphocytes. Nat Rev Immunol 2001;1:177-186.
77. Miller MM, Wang C, Parisini E, Coletta RD, Goto RM, Lee SY, Barral DC, Townes M, Roura-Mir C, Ford HL, Brenner MB, Dascher CC: Characterization of two avian MHC-like genes reveals an ancient origin of the CD1 family. Proc Natl Acad Sci USA 2005;102:8674-8679.
78. Salomonsen J, Sorensen MR, Marston DA, Rogers SL, Collen T, van Hateren A, Smith AL, Beal RK, Skjodt K, Kaufman J: Two CD1 genes map to the chicken MHC, indicating that CD1 genes are ancient and likely to have been present in the primordial MHC. Proc Natl Acad Sci USA 2005;102:8668-8673.
79. Porcelli SA, Modlin RL: The CD1 system. Antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 1999;17:297-329.
80. Personal communication, Dascher CC and Van Rhijn I.
81. Gumperz JE, Miyake S, Yamamura T, Brenner MB: Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625-636.
82. Lee PT, Benlagha K, Teyton L, Bendelac A: Distinct functional lineages of human Va24 natural killer T cells. J Exp Med 2002;195:637-641.
83. Johnston B, Kim CH, Soler D, Emoto M, Butcher EC: Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets. J Immunol 2003;171:2960-2969.
84. Hammond KJ, Pelikan SB, Crowe NY, Randle-Barrett E, Nakayama T, Taniguchi M, Smyth MJ, van Driel IR, Scollay R, Baxter AG, Godfrey DI: NKT cells are phenotypically and functionally diverse. Eur J Immunol 1999;29:3768-3781.
85. Ho LP, Urban BC, Jones L, Ogg GS, McMichael AJ: CD4(-)CD8alpha-alpha subset of CD1d-restricted NKT cells controls T cell expansion. J Immunol 2004;172:7350-7358.
86. Takahashi T, Chiba S, Nieda M, Azuma T, Ishihara S, Shibata Y, Juji T, Hirai H: Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 2002;168:3140-3144.
87. Pellicci DG, Hammond KJ, Uldrich AP, Baxter AG, Smyth MJ, Godfrey DI: A tatural killer T (NKT) cell developmental pathway involving a thymus-dependent NK1.1- CD4+ CD1d-dependent precursor stage. J Exp Med 2002;195:835-844.
88. Fiedler T, Walter W, Reichert TE, Maeurer MJ: Regulation of CD1d expression by murine tumor cells. Escape from immunosurveillance or alternate target molecules? Int J Cancer 2002;98: 389-397.
89. Zheng Z, Venkatapathy S, Rao G, Harrington CA: Expression profiling of B cell chronic lymphocytic leukemia suggests deficient GD1-mediated immunity, polarized cytokine response, altered adhesion, and increased intracellular protein transport and processing of leukemic cells. Leukemia 2002;16:2429-2437.
90. Fais F, Morabito F, Stelitano C, Callea V, Zanardi S, Scudeletti M, Varese P, Ciccone E, Grossi CE: CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer 2004;109:402-411.
91. Fais F, Tenca C, Cimino G, Coletti V, Zanardi S, Bagnara D, Saverino D, Zarcone D, De Rossi G, Ciccone E, Grossi CE: CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia 2005;19:551-556.
92. Marktel S, Magnani Z, Ciceri F, Cazzaniga S, Riddell SR, Traversari C, Bordignon C, Bonini C: Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003;101:1290-1298.
93. Takahashi T, Haraguchi K, Chiba S, Yasukawa M, Shibata Y, Hirai H: Valpha24+ natural killer T-cell responses against T-acute lymphoblastic leukaemia cells. Implications for immunotherapy. Br J Haematol 2003;122:231-239.
94. Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, Tokunaga K, Suzuki K, Kayagaki N, Yagita H, Hirai H, Juji T: TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001;97:2067-2074.
95. Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, Durrant S, Juji T: Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 2000;99:229-234.
96. Haginara M, Gansuvd B, Ueda Y, Tsuchiya T, Masui A, Tazume K, Inoue H, Kato S, Hotta T: Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematologic cells in vitro. A comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells. Cancer Immunol Immunother 2002;51:1-8.
97. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, Krasovsky J: A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003;197:1667-1676.
98. Fujii S, Shimizu K, Klimek V, Geller MD, Nimer SD, Dhodapkar MV: Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol 2003;122:617-622.
99. Sriram V, Cho S, Li P, O'Donnell PW, Dunn C, Hayakawa K, Blum JS, Brutkiewicz RR: Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells. Proc Natl Acad Sci USA 2002;99:8197-8202.
100. McKallip R, Li R, Ladisch S: Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 1999;163:3718-3726.
101. Santin AD, Ravindranath MH, Bellone S, Muthugounder S, Palmieri M, O'Brien TJ, Roman J, Cannon MJ, Pecorelli S: Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2004;111:613-618.
102. Dumonceaux T, Carlsen SA: Isogloboside biosynthesis in metastatic R3230AC cells results from a decreased GM3 synthase activity. Arch Biochem Biophys 2001;389:187-194.
103. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC: Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 1996;271:19530-19536.
104. Sietsma H, Veldman RJ, Kok JW: The involvement of sphingolipids in multidrug resistance. J Membr Biol 2001;181:153-162.
105. Margalit M, Ghazala SA, Alper R, Elinav E, Klein A, Doviner V, Sherman Y, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y: Glucocerebroside treatment ameliorates Con-A hepatitis by inhibition of NKT lymphocytes. Am J Physiol Gastrointest Liver Physiol 2005;289(5):G917-925.
106. Takeda K, Hayakawa Y, van Kaer L, Matsuda H, Yagita H, Okumura K: Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000;97:5498-5503.
107. Yoneda K, Morrii T, Nieda M, Tsukaguchi N, Amano I, Tanaka H, Yagi H, Narita N, Kimura H: The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk Res 2005;29:147-152.
108. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M: Cutting edge. Inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 1999;163:2387-2391.
109. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M: Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278: 1623-1626.
110. Nakagawa R, Motoki K, Nakamura H, Ueno H, Iijima R, Yamauchi A, Tsuyuki S, Inamoto T, Koezuka Y: Antitumor activity of alpha-galactosylceramide. KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol Res 1998;10:561-568.
111. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I: IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 2002;100:1728-1733.
112. Miyagi T, Takehara T, Tatsumi T, Kanto T, Suzuki T, Jinushi M, Sugimoto Y, Sasaki Y, Hori M, Hayashi N: CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer 2003;106:81-89.
113. Hayakawa Y, Rovero S, Forni G, Smyth MJ: Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 2003;100:9464-9469.
114. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T: The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL-)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999;189:1121-1128.
115. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K, Yagita H, Godfrey DI: Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 2002;99:1259-1266.
116. Osada T, Nagawa H, Shibata Y: Tumor-infiltrating effector cells of alpha-galactosylceramide-induced antitumor immunity in metastatic liver tumor. J Immune Based Ther Vaccines 2004;2:7.
117. Nakagawa R, Inui T, Nagafune I, Tazunoki Y, Motoki K, Yamauchi A, Hiroshima M, Habu Y, Nakashima H, Seki S. Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide. J Immunol 2004;172(11):6550-6557.
118. Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, Motoki K, Kamishohara M, Seki S: Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 2001; 166:6578-6584.
119. Delarbre C, Gachelin G: Injection of the immunomodulatory drug alpha-galactosylceramide results in the recruitment of a large population of antigen-presenting cells into the liver of C57BL/6 mice. Microbes Infect 2004;6:360-368.
120. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI: Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-668.
121. Smyth MJ, Crowe NY, Godfrey DI: NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001;13:459-463.
122. Crowe NY, Smyth MJ, Godfrey DI: A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002;196:119-127.
123. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, Kronenberg M, Seeger RC: Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 2001;167:3114-3122.
124. Ishihara S, Nieda M, Kitayama J, Osada T, Yabe T, Kikuchi A, Koezuka Y, Porcelli SA, Tadokoro K, Nagawa H, Juji T: Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro. J Immunol 2000;165:1659-1664.
125. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA: NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-520.
126. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, Berzofsky JA: Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198:1741-1752.
127. Park JM, Terabe M, van den Broeke LT, Donaldson DD, Berzofsky JA: Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int J Cancer 2005;114:80-87.
128. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE: Immune suppression and skin cancer development. Regulation by NKT cells. Nat Immunol 2000;1:521-525.
129. Yanagisawa K, Seino K, Ishikawa Y, Nozue M, Todoroki T, Fukao K: Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol 2002;168:6494-6499.
130. Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N, Akutsu Y, Motohashi S, Iizasa T, Endo H, Fujisawa T, Shinkai H, Taniguchi M: Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 1999;59:5102-5105.
131. Crough T, Purdie DM, Okai M, Maksoud A, Nieda M, Nicol AJ: Modulation of human Valpha24(+)Vbeta11(+) NKT cells by age, malignancy and conventional anticancer therapies. Br J Cancer 2004;91:1880-1886.
132. Kenna T, Golden-Mason L, Porcelli SA, Koezuka Y, Hegarty JE, O'Farrelly C, Doherty DG: NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol 2003;171:1775-1779.
133. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA: Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001;167:4046-4050.
134. Motohashi S, Kobayashi S, Ito T, Magara KK, Mikuni O, Kamada N, Iizasa T, Nakayama T, Fujisawa T, Taniguchi M: Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Int J Cancer 2002;102: 159-165.
135. Erratum in: Int J Cancer 2003;104:799.
136. Konishi J, Yamazaki K, Yokouchi H, Shinagawa N, Iwabuchi K, Nishimura M: The characteristics of human NKT cells in lung cancer. CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Hum Immunol 2004;65:1377-1388.
137. Dhodapkar KM, Cirignano B, Chamian F, Zagzag D, Miller DC, Finlay JL, Steinman RM: Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 2004;109:893-899.
138. Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi Z, Asgharzadeh S, Groshen S, Wilson SB, Seeger RC: Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 2004;199:1213-1221.
139. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM: A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8:3702-3709.
140. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, Juji T, Macfarlane DJ, Nicol AJ: Therapeutic activation of Valpha24+ Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004;103: 383-389.
141. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T: A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005; 11:1910-1917.
142. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M, Hutchinson A, Geller M, Liu N, Annable R, Shay J, Kirchhoff K, Nishi N, Ando Y, Hayashi K, Hassoun H, Steinman RM, Dhodapkar MV: Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005;201: 1503-1517.
143. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, Mathew B, Schmidt RR, Lunt SJ, Williams KJ, Stratford IJ, Harris AL, Cerundolo V: Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 2004;114:1800-1811.
144. Haraguchi K, Takahashi T, Matsumoto A, Asai T, Kanda Y, Kurokawa M, Ogawa S, Oda H, Taniguchi M, Hirai H, Chiba S: Host-residual invariant NKT cells attenuate graft-versus-host immunity. J Immunol 2005;175:1320-1328.
145. Haraguchi K, Takahashi T, Hiruma K, Kanda Y, Tanaka Y, Ogawa S, Chiba S, Miura O, Sakamaki H, Hirai H: Recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004;34:595-602.
146. Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R, Strober S: Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999;189:1073-1081.
147. Zeng D, Gazit G, Dejbakhsh-Jones S, Balk SP, Snapper S, Taniguchi M, Strober S: Heterogeneity of NK1.1+ T cells in the bone marrow. Divergence from the thymus. J Immunol 1999;163:5338-5345.
148. Exley MA, Tahir SM, Cheng O, Shaulov A, Joyce R, Avigan D, Sackstein R, Balk SP: A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol 2001;167:5531-5534.
149. Lan F, Zeng D, Higuchi M, Huie P, Higgins JP, Strober S: Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease 'Natural suppressor' cells. J Immunol 2001;167: 2087-2096.
150. Lan F, Zeng D, Higuchi M, Higgins JP, Strober S: Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant 2003;9:355-363.
151. Margalit M, Ilan Y, Ohana M, Safadi R, Alper R, Sherman Y, Doviner V, Rabbani E, Engelhardt D, Nagler A: Adoptive transfer of small numbers of DX5+ cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation. A potential role for NKT lymphocytes. Bone Marrow Transplant 2005;35:191-197.
152. Morecki S, Panigrahi S, Pizov G, Yacovlev E, Gelfand Y, Eizik O, Slavin S: Effect of KRN7000 on induced graft-vs-host disease. Exp Hematol 2004;32:630-637.
153. Hashimoto D, Asakura S, Miyake S, Yamamura T, van Kaer L, Liu C, Tanimoto M, Teshima T: Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol 2005;174:551-556.
154. Seino KI, Fukao K, Muramoto K, Yanagisawa K, Takada Y, Kakuta S, Iwakura Y, van Kaer L, Takeda K, Nakayama T, Taniguchi M, Bashuda H, Yagita H, Okumura K: Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci USA 2001;98:2577-2581.
155. Higuchi M, Zeng D, Shizuru J, Gworek J, Dejbakhsh-Jones S, Taniguchi M, Strober S: Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NKT cells and clonal deletion. J Immunol 2002;169:5564-5570.
156. Ikehara Y, Yasunami Y, Kodama S, Maki T, Nakano M, Nakayama T, Taniguchi M, Ikeda S: CD4(+) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J Clin Invest 2000;105:1761-1767.
157. Larsson LC, Anderson P, Widner H, Korsgrent O: Enhanced survival of porcine neural xenografts in mice lacking CD1d1, but no effect of NK1.1 depletion. Cell Transplant 2001;10:295-304.
158. Boyson JE, Rybalov B, Koopman LA, Exley M, Balk SP, Racke FK, Schatz F, Masch R, Wilson SB, Strominger JL: CD1d and invariant NKT cells at the human maternal-fetal interface. Proc Natl Acad Sci USA 2002;99:13741-13746.
159. Galante NZ, Ozaki KS, Cenedeze MA, Kallas EG, Salomao R, Pacheco-Silva A, Camara NO: Frequency of Valpha24+Vbeta11+ NKT cells in peripheral blood of human kidney transplantation recipients. Int Immunopharmacol 2005;5:53-58.
160. Poulton LD, Smyth MJ, Hawke CG, Silveira P, Shepherd D, Naidenko OV, Godfrey DI, Baxter AG: Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol 2001;13:887-896.
161. Lehuen A, Lantz O, Beaudoin L, Laloux V, Carnaud C, Bendelac A, Bach JF, Monteiro RC: Overexpression of natural killer T cells protects Valphal4- Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998;188:1831-1839.
162. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, Miura T, Haba T, Scherer DC, Wei J, Kronenberg M, Koezuka Y, Van Kaer L: The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in nonobese diabetic mice. Nat Med 2001;7:1052-1056.
163. Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG: alpha/beta-T cell receptor (TCR) +CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL-)-4 and/or IL-10. J Exp Med 1998;187:1047-1056.
164. Mizuno M, Masumura M, Tomi C, Chiba A, Oki S, Yamamura T, Miyake S: Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J Autoimmun 2004;23:293-300.
165. Personal communication, Serreze D.
166. Naumov YN, Bahjat KS, Gausling R, Abraham R, Exley MA, Koezuka Y, Balk SB, Strominger JL, Clare-Salzer M, Wilson SB: Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci USA 2001;98:13838-13843.
167. Matsuki N, Stanic AK, Embers ME, Van Kaer L, Morel L, Joyce S: Genetic dissection of V alpha 14J alpha 18 natural T cell number and function in autoimmune-prone mice. J Immunol 2003;170: 5429-5437.
168. Wilson SB, Kent SC, Horton HF, Hill AA, Bollyky PL, Hafler DA, Strominger JL, Byrne MC: Multiple differences in gene expression in regulatory Valpha 24Jalpha Q T cells from identical twins discordant for type I diabetes. Proc Natl Acad Sci USA 2000;97:7411-7416.
169. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, Porcelli S, Maclaren N: Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002;109: 131-140.
170. Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T: Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000;164:4375-4381.
171. Araki M, Kondo T, Gumperz JE, Brenner MB, Miyake S, Yamamura T: Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol 2003;15:279-288.
172. Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V: Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001;194:1789-1799.
173. Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, Joyce S, Sriram S, Koezuka Y, Van Kaer L: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001;194:1801-1811.
174. Pal E, Tabira T, Kawano T, Taniguchi M, Miyake S, Yamamura T. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells. J Immunol 2001;166:662-668.
175. Forestier C, Molano A, Im JS, Dutronc Y, Diamond B, Davidson A, Illarionov PA, Besra GS, Porcelli SA: Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black ¥ New Zealand White)F1 mice. J Immunol 2005;175:763-770.
176. Singh AK, Yang JQ, Parekh VV, Wei J, Wang CR, Joyce S, Singh RR, van Kaer L: The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur J Immunol 2005;35:1143-1154.
177. Oishi Y, Sumida T, Sakamoto A, Kita Y, Kurasawa K, Nawata Y, Takabayashi K, Takahashi H, Yoshida S, Taniguchi M, Saito Y, Iwamoto I: Selective reduction and recovery of invariant Valpha24JalphaQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J Rheumatol 2001;28:275-283.
178. Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T: Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001;44:1127-1138.
179. Van der Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, Polman CH, Rustemeyer T, Lips P, van den Eertwegh AJ, Giaccone G, Scheper RJ, Pinedo HM: Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001;100:144-148.
180. Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, He XS, Koning F, Mikayama T, van de Water J, Coppel RL, Kaplan M, Gershwin ME: Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002;123:1031-1043.
181. Sonoda KH, Stein-Streilein J: Ocular immune privilege and CD1d-reactive natural killer T cells. Cornea 2002;21:S33-38.
182. Sonoda KH, Exley M, Snapper S, Balk SP, Stein-Streilein J: CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med 1999;190:1215-1226.
183. Sonoda KH, Faunce DE, Taniguchi M, Exley M, Balk S, Stein-Streilein J: NKT cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J Immunol 2001;166:42-50.
184. Sonoda KH, Stein-Streilein J: CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance. Eur J Immunol 2002 Mar;32(3):848-857.
185. Margenthaler JA, Landeros K, Kataoka M, Flye MW: CD1-dependent natural killer (NK1.1(+)) T cells are required for oral and portal venous tolerance induction. J Surg Res 2002;104:29-35.
186. Pasquier B, Yin L, Fondaneche MC, Relouzat F, Bloch-Queyrat C, Lambert N, Fischer A, de Saint-Basile G, Latour S: Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 2005;201:695-701.
187. Chung B, Aoukaty A, Dutz J, Terhorst C, Tan R: Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J Immunol 2005;174:3153-3157.
188. Nichols KE, Hom J, Gong SY, Ganguly A, Ma CS, Cannons JL, Tangye SG, Schwartzberg PL, Koretzky GA, Stein PL: Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med 2005;11:340-345.
189. Eberl G, Lowin-Kropf B, MacDonald HR: Cutting edge. NKT cell development is selectively impaired in Fyn-deficient mice. J Immunol 1999;163:4091-4094.
190. Gadue P, Morton N, Stein PL: The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med 1999;190:1189-1196.
191. Latour S, Roncagalli R, Chen R, Bakinowski M, Shi X, Schwartzberg PL, Davidson D, Veillette A: Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation. Nat Cell Biol 2003;5:149-154.
192. Nichols KE, Hom J, Gong SY, Ganguly A, Ma CS, Cannons JL, Tangye SG, Schwartzberg PL, Koretzky GA, Stein PL: Regulation of NKT cell development by SAP, the protein defective in XLP. Nat Med 2005;11:340-345.
193. Macon WR, Williams ME, Greer JP, Hammer RD, Glick AD, Collins RD, Cousar JB: Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes. Blood 1996;87: 1474-1483.
194. Ng SB, Lai KW, Murugaya S, Lee KM, Loong SLE, Fook-Chong S, Tao M, Sng I: Nasal-type extranodal natural killer/T cell lymphomas. A clinicopathologic and genotypic study of 42 cases in Singapore. Mod Path 2004;17:1097-1107.
195. Ko YH, Cho EY, Lee SS, Huh JR, Chang HK, Yang WI, Kim CW, Kim SW, Ree HJ: NK and NK-like T-cell lymphoma in extranasal sites. A comparative clinicopathological study according to site and EBV status. Histopathology 2004;44:480-489.